+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prevalence of dyslipidemia and dysglycaemia in HIV infected patients



Prevalence of dyslipidemia and dysglycaemia in HIV infected patients



East African Medical Journal 85(1): 10-17



Highly active antiretroviral therapy (HAART) has dramatically reduced AIDS morbidity and mortality, however long-term metabolic consequences including dysglycaemia and dyslipidemia have raised concern regarding accelerated cardiovascular disease risk. To determine the period prevalence of dyslipidemia and dysglycaemia in HIV-infected patients. Cross-sectional comparative group study. Kenyatta National Hospital, a tertiary HIV dedicated out-patient facility. Consecutive HIV- positive adult patients. Dyslipidemia: presence of raised total or LDL cholesterol or low HDL cholesterol, or raised triglycerides. Dysglycaemia: presence of impaired fasting glucose or impaired glucose tolerance, or diabetes mellitus. Between January and April 2006, out of 342 screened patients, 295 were recruited and 58% were females. One hundred and thirty four (45%) were on HAART, 82% of whom were on stavudine, lamivudine and either nevirapine or efavirenz. Overall prevalence of dyslipidemiawas 63.1% and dysglycaemia was 20.7%. High total cholesterol occurred in 39.2% of HAART and 10.0% HAART naive patients (p<0.0001, OR 5.18, CI 3.11-10.86), whereas high LDL cholesterol occurred in 40.8% and in 11.2% respectively (p<0.0001, OR 5.43, CI 2.973-9.917). HDL levels were low in 14.6% and 51.3% among HAART and HAART naive patients, respectively, (p<0.0001, OR 0.16, CI 0.091-0.29) while high triglycerides occurred in 25.6% and 22.5% respectively (p=0.541 OR 1.184 CI 0.688-2.037). Among patients on HAART compared to HAART naive patients, diabetes was found in 1.5% against 1.2% (p=0.85), impaired fasting in 2.2% against 0.6% (p=0.30) and impaired glucose tolerance in 16.4% against 21.1% (p=0.22), respectively. HIV- infected patients demonstrated a high prevalence of dyslipidemia. HAART use was associated with high levels of total, and LDL cholesterol and high triglyceride levels, an established athrogenic lipid profile. However, HAART was not associated with low HDL cholesterol and had no significant effect on dysglycaemia.

(PDF emailed within 0-6 h: $19.90)

Accession: 055157398

Download citation: RISBibTeXText

PMID: 18543521

DOI: 10.4314/eamj.v85i1.9600


Related references

Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. Journal of Infection 50(4): 331-337, 2005

Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients. Plos One 11(3): E0151911, 2016

Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Canadian Journal of Cardiology 26(9): E330-E335, 2011

Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. Aids Research and Therapy 9(1): 31, 2012

Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): results of the Dyslipidemia International Study (DYSIS). Medicina 50(1): 44-53, 2016

Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis. African Health Sciences 13(4): 1107-1116, 2015

Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians. Annals of African Medicine 12(1): 24-28, 2013

Prevalence of Dyslipidemia Among Antiretroviral-Naive HIV-Infected Individuals in China. Medicine 94(48): E2201, 2016

Prevalence of lipodystrophy and risk factors for dyslipidemia in HIV-infected children in Brazil. Brazilian Journal of Infectious Diseases 18(4): 394-399, 2014

High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy. Pediatric Infectious Disease Journal 35(1): E1-E7, 2016

Prevalence of dyslipidemia and borderline dyslipidemia in aging residents from Beijing communities. Zhonghua Yi Xue Za Zhi 93(46): 3675-3679, 2014

Dyslipidemia among HIV-infected patients. Annals of African Medicine 13(3): 142, 2014

Prevalence of dyslipidemia and borderline dyslipidemia and other risk factors of coronary heart disease in residents from Beijing communities. Zhonghua Xin Xue Guan Bing Za Zhi 38(2): 175-180, 2011

Prevalence of dyslipidemia and factors affecting dyslipidemia in young adults with type 1 diabetes: evaluation of statin prescribing. Journal of Pediatric Endocrinology and Metabolism 2019, 2019

Management of dyslipidemia in HIV-infected patients. Mmw Fortschritte der Medizin 154 Suppl 1: 34-36, 2012